Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Kiadis Pharma    KDS   NL0011323407

KIADIS PHARMA (KDS)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 05:35:18 pm
8.18 EUR   -2.15%
04/10KIADIS PHARMA NV : annual earnings release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
7.93(c) 8.07(c) 8.26(c) 8.36(c) 8.18(c) Last
95 746 68 430 68 017 31 819 29 078 Volume
-4.46% +1.77% +2.35% +1.21% -2.15% Change
More quotes
Financials (EUR)
Sales 2018 -
EBIT 2018 -21,8 M
Net income 2018 -25,0 M
Finance 2018 4,30 M
Yield 2018 -
Sales 2019 2,07 M
EBIT 2019 -24,6 M
Net income 2019 -27,1 M
Debt 2019 5,40 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 101x
Capitalization 203 M
More Financials
Company
Kiadis Pharma specializes in the research and development of cellular immunotherapy products for the treatment of terminal-phase blood cancer. At the end of 2017, the group had a portfolio of 2 products in phase III of clinical development (ATIR101; treatment of acute leukemia and ATIR201;... 
More about the company
Surperformance© ratings of Kiadis Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on KIADIS PHARMA
11/13KIADIS PHARMA : to present at upcoming investor conferences in November 2018
GL
11/09KIADIS PHARMA : strengthens core team with three senior appointments
AQ
11/08KIADIS PHARMA : strengthens core team with three senior appointments
AQ
11/07KIADIS PHARMA N. V. : Kiadis Pharma announces abstracts and presentations for th..
AQ
10/22KIADIS PHARMA : raises EUR31.2 million in a private placement of 3.9 million new..
AQ
10/19KIADIS PHARMA : raises €31.2 million in a private placement of 3.9 million new s..
AQ
10/18KIADIS PHARMA : launches a private placement of approximately 3.7 million new sh..
AQ
10/12KIADIS PHARMA : provides regulatory and clinical update on ATIR101
AQ
10/01KIADIS PHARMA : Corporate Officers and Executives' transactions in the company's..
CO
09/11KIADIS PHARMA : announces two senior management appointments
AQ
More news
Analyst Recommendations on KIADIS PHARMA
More recommendations
Sector news : Biotechnology & Medical Research - NEC
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart KIADIS PHARMA
Duration : Period :
Kiadis Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KIADIS PHARMA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 18,3 €
Spread / Average Target 119%
EPS Revisions
Managers
NameTitle
Arthur K. Lahr Chief Executive Officer
Mark A. Wegter Chairman-Supervisory Board
Jan Feijen Chief Operations Officer
Scott A. Holmes Chief Financial Officer
Andrew S. Sandler Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
KIADIS PHARMA5.54%231
IQVIA HOLDINGS INC24.11%24 306
CELLTRION, INC.--.--%24 149
LONZA GROUP16.86%23 031
INCYTE CORPORATION-28.95%14 320
SEATTLE GENETICS, INC.14.02%9 843